Slowly getting the rental fleet in line with the rental seamd, all will then fall into place. Hate that they sold equipment rental division I think it had long term potential to be a money maker.
Coming quarter could be a miss and I think it is priced into the market? If buying (longterm) $12 is a bump in the road. Trading is where Wall Street takes money from the little man, be honest traders.
"proceeds are intended to be used to (i) finance the proposed separation of the Company's global equipment rental business (the "Spin-Off") and (ii) pay fees and other transaction expenses in connection with the Spin-Off transactions.'
executing as planned. If earning start to creep up at this point....
Uber is the new poverty. Of course you can combine in with multiple jobs and make a living. Uber is aimed at taxi's and I use Hertz & Uber.Never has replaced my need to use Hertz.
Afraid of Perlman games. Also aware bad faith at this point on his part and the courts will come down hard. I don't think Perlman plays kamikaze but would like debtors think he is willing.
Accelerated approval and Breakthrough Status are the one's that skyrocket as they foretell much better prospects are likely
And, every drug development company hypes fast track status. GLTA, it's the small investor and his money wanted as always.
Somebody must be paying attention. It's back up a penny? In CC they definitely said there were still in process of working off excess inventory to match rental demand and were competing on price. A turnaround hoped for in second half?
In the middle of the last bad quarter? Listened to last CC and it does look Hertz will have one more quarter of kitchen sink earnings? Anyone else hear the CC differently?
This Wall Street Darling no doubt lead to huge losses by those who invest other peoples money? That is who should be going to jail. They were pros and know the product (stock) they buy for their clients accounts.
Ha, I know how it works and I also know those investing other people's money never go to jail. A few really over the top sacrificial lams get some time. Of course the criminals also have great lawyers and get out much quicker than expected and go back to live the lavish lifestyle immediately upon release.
And the folks who paid far too much for their healthcare, this effects us all in our premiums, that is all perfectly legal and you don't count. What they do in gouging consumers is all legal.
If the merger doesn't happen it would be nice to see pay reflect performance focus on financials of company.
As CEO at RITE AID CORP, John T. Standley made $10,877,317 in total compensation. Of this total $1,150,000 was received as a salary, $2,991,291 was received as a bonus, $3,032,895 was received in stock options, $3,411,852 was awarded as stock and $291,279 came from other types of compensation. This information is according to proxy statements filed for the 2015 fiscal year.
That is a fat payday
CC told the story to those listening
Unfortunately, the weak industry revenue environment in the quarter masked the significant improvements we are making in other areas. In particular, we are making great progress on our agenda to drive costs take-outs and quality improvements.
The way the insiders are buying it looks like a lot of bad was cleaned out last quarter. Quick rebound coming as the best season is now upon us. Good headlines over the next few months....
Think their telling us the last two quarters were kitchen sink and everything bad to be written down (it was an ugly quarter!). Positive surprises to be delivered in second half.
34.11% short. Wall Street has much more info on this one than we ever will. After they get one more sizable dip to exit I plan to go long for the long term (years). I'm expecting a hard summer for the market and a better entry from the short games being played. Expect same shorts will be going long with me. Two or more years out it will be a big win.
GLTA, especially the small investors
Nice share from one that has been through the enoxaprin and how much an oral formulation means. Adherence is the biggest obstacle to any drug therapy. Adherence is also something the FDA is really starting to focus on.
The get rick quick crowd has to move on before success of a second trial can be calculated in. Or, company may partner or just sell out?
Wild guess, a surprise bounce when company announces a second trial with expedited approval. Non-inferiority with oral dosing and some bleeding advantages should be as easy sell.